Author:
Chow Melissa,Sangalang Elizabeth A.,Chow Christine,Daud Adil I.
Publisher
Springer International Publishing
Reference69 articles.
1. Cancer.org. Melanoma skin cancer statistics. https://www.cancer.org/cancer/melanoma-skin-cancer/about/key-statistics.html. In: . Accessed 29 Jan 2021.
2. Carlson RD, Flickinger JC, Snook AE. Talkin’ toxins: from Coley’s to modern cancer immunotherapy. Toxins. 2020;12:241.
3. Atkins MB, Lotze MT, Dutcher JP, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999;17:2105.
4. Curti B, Daniels GA, McDermott DF, et al. Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIMSM registry. J Immunother Cancer. 2017;5:102.
5. Pachella LA, Madsen LT, Dains JE. The toxicity and benefit of various dosing strategies for Interleukin-2 in metastatic melanoma and renal cell carcinoma. J Adv Pract Oncol. 2015;6:212–21.